VRDN

Viridian Therapeutics, Inc.\DE

NasdaqAdd to watchlist

Healthcare · Biotechnology

$23.16

+$0.08+0.35%

Delayed · 2026-08-31T20:00:00.000Z · marketstack

2 open-market sales on file ($419K), none of them under a pre-arranged plan. Who, and when

Aug 24, 2026$23.16

−$0.86−3.58%over 1M

Session

Day range83% of range

$22.62$23.27

Fundamentals

Visualize fundamentals and more

Market cap: -
P/E ratio: -

Revenue grew +23359.93% in FY2025, +23351.07% faster than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AFeb 2026 10-KMar 2025

added: 83
dropped: 94
re-drafted: 57

Out of 316 passages in this year’s Item 1A.

New this year

Our business, financial condition, and operating results may be affected by a number of factors, whether currently known or unknown, including but not limited to those described below. Any one or more of such factors could directly or indirectly cause our …

176 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
China
Litigation
Data privacy
Product recalls
Going concern
Patent expiry

And 15 more.

FDA approval
We expect our losses to increase as our product candidates continue advancing through clinical development and as new product candidates enter clinical trials and then advance through clinical development. It may be several years, if ever, before we complete …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

21 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Aug 31, 2026 · the last close

Viridian Therapeutics, Inc.\DE investor relations

What VRDN has filed with the SEC. This is not Viridian Therapeutics, Inc.\DE’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Viridian Therapeutics, Inc.\DE

Also filed under Biotechnology, ranked by how closely they sit beside VRDN.

MRNAModerna, Inc.compare with VRDN
ROIVRoivant Sciences Ltd.compare with VRDN
VRTX

Vertex Pharmaceuticals Inc. / MA

XENEXenon Pharmaceuticals Inc.compare with VRDN

NVONovo Nordisk A Scompare with VRDN

Ask about Viridian Therapeutics, Inc.\DE

The assistant answers from what VRDN has actually filed: 13 annual reports filed with the SEC, 15 Form 4 filings from the last year and 3 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from VRDN's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Viridian Therapeutics, Inc.\DE each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Viridian Therapeutics, Inc.\DE

Be told the moment a VRDN insider trades
Put Viridian Therapeutics, Inc.\DE on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Viridian Therapeutics, Inc.\DE's income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Viridian Therapeutics, Inc.\DE's fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
China
Litigation
Data privacy
Product recalls
Going concern
Patent expiry

And 15 more.

FDA approval
We expect our losses to increase as our product candidates continue advancing through clinical development and as new product candidates enter clinical trials and then advance through clinical development. It may be several years, if ever, before we complete …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AFeb 2026 10-KMar 2025

added: 83
dropped: 94
re-drafted: 57

Out of 316 passages in this year’s Item 1A.

New this year

Our business, financial condition, and operating results may be affected by a number of factors, whether currently known or unknown, including but not limited to those described below. Any one or more of such factors could directly or indirectly cause our …

176 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add